Madison Elsaadi
Stock Analyst at B. Riley Securities
(4.73)
# 688
Out of 4,676 analysts
61
Total ratings
58.3%
Success rate
46.5%
Average return
Main Sectors:
Stocks Rated by Madison Elsaadi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals | Initiated Coverage: Buy | $17 → $12 | $5.33 | +125.14% | 6 | Aug 10, 2026 | |
| CMPS COMPASS Pathways | Maintained: Buy | $17 → $22 | $14.20 | +54.93% | 2 | Aug 6, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Reiterated: Buy | $123 | $86.73 | +41.82% | 7 | Aug 5, 2026 | |
| CAPR Capricor Therapeutics | Downgraded: Hold | $63 → $5 | $6.80 | -26.47% | 7 | Jul 31, 2026 | |
| WVE Wave Life Sciences | Reiterated: Buy | $31 → $22 | $5.12 | +329.69% | 15 | Jul 31, 2026 | |
| SPRB Spruce Biosciences | Initiated Coverage: Buy | $160 | $58.65 | +172.80% | 1 | Jul 13, 2026 | |
| ETON Eton Pharmaceuticals | Reiterated: Buy | $40 | $64.43 | -37.92% | 14 | Jun 25, 2026 | |
| OVID Ovid Therapeutics | Reiterated: Buy | $5 | $2.82 | +77.30% | 4 | May 13, 2026 | |
| IRD Opus Genetics | Maintained: Buy | $9 → $10 | $4.03 | +148.14% | 2 | Apr 30, 2026 | |
| FENC Fennec Pharmaceuticals | Initiated Coverage: Buy | $16 | $11.40 | +40.35% | 1 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $179 | $205.40 | -12.85% | 1 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $7.67 | n/a | 1 | Jan 23, 2025 |
Vanda Pharmaceuticals
Aug 10, 2026
Initiated Coverage: Buy
Price Target: $17 → $12
Current: $5.33
Upside: +125.14%
COMPASS Pathways
Aug 6, 2026
Maintained: Buy
Price Target: $17 → $22
Current: $14.20
Upside: +54.93%
Arrowhead Pharmaceuticals
Aug 5, 2026
Reiterated: Buy
Price Target: $123
Current: $86.73
Upside: +41.82%
Capricor Therapeutics
Jul 31, 2026
Downgraded: Hold
Price Target: $63 → $5
Current: $6.80
Upside: -26.47%
Wave Life Sciences
Jul 31, 2026
Reiterated: Buy
Price Target: $31 → $22
Current: $5.12
Upside: +329.69%
Spruce Biosciences
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $160
Current: $58.65
Upside: +172.80%
Eton Pharmaceuticals
Jun 25, 2026
Reiterated: Buy
Price Target: $40
Current: $64.43
Upside: -37.92%
Ovid Therapeutics
May 13, 2026
Reiterated: Buy
Price Target: $5
Current: $2.82
Upside: +77.30%
Opus Genetics
Apr 30, 2026
Maintained: Buy
Price Target: $9 → $10
Current: $4.03
Upside: +148.14%
Fennec Pharmaceuticals
Feb 12, 2026
Initiated Coverage: Buy
Price Target: $16
Current: $11.40
Upside: +40.35%
Oct 1, 2025
Initiated Coverage: Buy
Price Target: $179
Current: $205.40
Upside: -12.85%
Jan 23, 2025
Reiterated: Buy
Price Target: $11
Current: $7.67
Upside: n/a